NASDAQ:CDMO

Avid Bioservices Stock Forecast, Price & News

$23.11
+0.41 (+1.81 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$22.06
$23.15
50-Day Range
$18.93
$23.85
52-Week Range
$5.39
$24.40
Volume267,591 shs
Average Volume667,581 shs
Market Capitalization$1.41 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.22
30 days | 90 days | 365 days | Advanced Chart
Receive CDMO News and Ratings via Email

Sign-up to receive the latest news and ratings for Avid Bioservices and its competitors with MarketBeat's FREE daily newsletter.


Avid Bioservices logo

About Avid Bioservices

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, purification, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. It serves biotechnology and pharmaceutical companies. Avid Bioservices, Inc. has a process development and manufacturing agreement with Oragenics, Inc. to develop coronavirus vaccine. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.86 out of 5 stars

Medical Sector

154th out of 2,099 stocks

Pharmaceutical Preparations Industry

68th out of 830 stocks

Analyst Opinion: 1.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Avid Bioservices (NASDAQ:CDMO) Frequently Asked Questions

Is Avid Bioservices a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Avid Bioservices stock.
View analyst ratings for Avid Bioservices
or view top-rated stocks.

What stocks does MarketBeat like better than Avid Bioservices?

Wall Street analysts have given Avid Bioservices a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Avid Bioservices wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Avid Bioservices' next earnings date?

Avid Bioservices is scheduled to release its next quarterly earnings announcement on Tuesday, June 29th 2021.
View our earnings forecast for Avid Bioservices
.

How were Avid Bioservices' earnings last quarter?

Avid Bioservices, Inc. (NASDAQ:CDMO) issued its earnings results on Sunday, March, 7th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.04. The biopharmaceutical company earned $21.81 million during the quarter, compared to analyst estimates of $20 million. Avid Bioservices had a net margin of 5.51% and a trailing twelve-month return on equity of 7.98%.
View Avid Bioservices' earnings history
.

How has Avid Bioservices' stock been impacted by Coronavirus?

Avid Bioservices' stock was trading at $4.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CDMO shares have increased by 412.4% and is now trading at $23.11.
View which stocks have been most impacted by COVID-19
.

When did Avid Bioservices' stock split? How did Avid Bioservices' stock split work?

Avid Bioservices's stock reverse split on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split.

What price target have analysts set for CDMO?

3 brokerages have issued twelve-month price objectives for Avid Bioservices' shares. Their forecasts range from $9.00 to $22.00. On average, they anticipate Avid Bioservices' stock price to reach $17.33 in the next year. This suggests that the stock has a possible downside of 25.0%.
View analysts' price targets for Avid Bioservices
or view top-rated stocks among Wall Street analysts.

Who are Avid Bioservices' key executives?

Avid Bioservices' management team includes the following people:
  • Mr. Daniel R. Hart, Chief Financial Officer (Age 48, Pay $488.87k)
  • Mr. Mark R. Ziebell, VP, Gen. Counsel & Corp. Sec. (Age 57, Pay $662.28k)
  • Mr. Nicholas Stewart Green, Pres, CEO & Director (Age 56)
  • Mr. Richard Richieri, Chief Operations Officer (Age 56)
  • Ms. Lorna Larson, Sr. Director of HR
  • Mr. Timothy Compton, Chief Commercial Officer
  • Dr. Shelley P. M. Fussey, VP of Intellectual Property (Age 55)
  • Ms. Tracy L. Kinjerski, VP of Bus. Operations
  • Dr. Harold F. Dvorak, Medical & Scientific Advisor
  • Prof. Alan J. Schroit, Medical & Scientific Advisor

What is Roger Lias' approval rating as Avid Bioservices' CEO?

2 employees have rated Avid Bioservices CEO Roger Lias on Glassdoor.com. Roger Lias has an approval rating of 49% among Avid Bioservices' employees. This puts Roger Lias in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Avid Bioservices' key competitors?

What other stocks do shareholders of Avid Bioservices own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Technologies (ARRY), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Micron Technology (MU), QUALCOMM (QCOM), NVIDIA (NVDA), Novavax (NVAX) and Pfizer (PFE).

What is Avid Bioservices' stock symbol?

Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."

Who are Avid Bioservices' major shareholders?

Avid Bioservices' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.85%), Iszo Capital Management LP (3.86%), AltraVue Capital LLC (2.31%), Russell Investments Group Ltd. (1.98%), Nuveen Asset Management LLC (1.68%) and Kornitzer Capital Management Inc. KS (1.63%). Company insiders that own Avid Bioservices stock include Daniel R Hart, Daniel Ryan Hart, Joseph Carleone, Mark R Bamforth, Mark R Ziebell, Patrick D Walsh and Richard B Hancock.
View institutional ownership trends for Avid Bioservices
.

Which institutional investors are selling Avid Bioservices stock?

CDMO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Los Angeles Capital Management LLC, Morgan Stanley, Intrinsic Edge Capital Management LLC, Kennedy Capital Management Inc., Pier Capital LLC, AltraVue Capital LLC, and Prudential Financial Inc.. Company insiders that have sold Avid Bioservices company stock in the last year include Daniel R Hart, and Mark R Ziebell.
View insider buying and selling activity for Avid Bioservices
or view top insider-selling stocks.

Which institutional investors are buying Avid Bioservices stock?

CDMO stock was acquired by a variety of institutional investors in the last quarter, including Palisade Capital Management LLC NJ, Nuveen Asset Management LLC, Goldman Sachs Group Inc., Dimensional Fund Advisors LP, BlackRock Inc., Jennison Associates LLC, Calamos Advisors LLC, and Schonfeld Strategic Advisors LLC. Company insiders that have bought Avid Bioservices stock in the last two years include Daniel Ryan Hart, Joseph Carleone, Mark R Bamforth, Patrick D Walsh, and Richard B Hancock.
View insider buying and selling activity for Avid Bioservices
or or view top insider-buying stocks.

How do I buy shares of Avid Bioservices?

Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avid Bioservices' stock price today?

One share of CDMO stock can currently be purchased for approximately $23.11.

How much money does Avid Bioservices make?

Avid Bioservices has a market capitalization of $1.41 billion and generates $59.70 million in revenue each year. The biopharmaceutical company earns $-10,470,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis.

How many employees does Avid Bioservices have?

Avid Bioservices employs 222 workers across the globe.

What is Avid Bioservices' official website?

The official website for Avid Bioservices is www.avidbio.com.

Where are Avid Bioservices' headquarters?

Avid Bioservices is headquartered at 2642 Michelle Drive Suite 200, TUSTIN CA, 92780.

How can I contact Avid Bioservices?

Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The biopharmaceutical company can be reached via phone at 714-508-6100 or via email at [email protected]


This page was last updated on 6/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.